RDY vs. RVMD: Dr. Reddy's Laboratories vs. Revolution Medicines Stock Comparison

Company Profile

Dr. Reddy's Laboratories (RDY) and Revolution Medicines (RVMD) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but RDY is classified in Pharmaceuticals while RVMD is classified in Biotechnology.

Dr. Reddy's Laboratories (RDY) has more than two decades of public-market history since April 11, 2001, whereas Revolution Medicines (RVMD) listed on February 13, 2020 and has a much shorter record to draw on.

Revolution Medicines (RVMD) trades as ordinary local shares, while Dr. Reddy's Laboratories (RDY) trades as an ADR — compare with FX exposure, depositary-program fees, and dividend-withholding-tax differences in mind.

Price Performance

Cumulative Growth

Trailing Returns

Calendar-Year Returns

Performance Metrics

Risk Profile

Drawdown History

Return Distribution

Risk Metrics

Revolution Medicines (RVMD) has an aggressive beta of 1.42, indicating higher sensitivity to broad-market moves, while Dr. Reddy's Laboratories (RDY) is defensive at 0.30 and tends to be less market-sensitive — they sit on opposite ends of the beta spectrum.

Risk-Adjusted Performance

Risk-Return Positioning

Risk-Adjusted Metrics

Profitability

Revolution Medicines (RVMD) reports a negative ROE of -93.56%; negative ROE can reflect losses or negative shareholders’ equity, so it is harder to read as capital efficiency. Meanwhile Dr. Reddy's Laboratories (RDY) reports 7.34%, ranking against industry peers normally.

Dr. Reddy's Laboratories (RDY) at 8.49% retains a top-quartile share of revenue as profit, ahead of Revolution Medicines (RVMD) at 0.00%, which keeps about the industry-typical share.

Revolution Medicines (RVMD) reports a negative operating margin of -188.88%, usually indicating that operating costs exceeded revenue at the operating-income line. Meanwhile Dr. Reddy's Laboratories (RDY) reports 14.73%, ranking against industry peers normally.

Profitability Metrics

Growth

Only one side can be read here: Dr. Reddy's Laboratories (RDY) reports revenue growth of 3.19%, ranked against its industry; Revolution Medicines (RVMD) has no revenue growth figure this period.

Only one side can be read here: Dr. Reddy's Laboratories (RDY) reports EPS growth of -24.14%, ranked against its industry; Revolution Medicines (RVMD) has no EPS growth figure this period.

Growth Metrics

Financial Strength

Revolution Medicines (RVMD) at 8.36 keeps current ratio within its industry’s typical mid-range, while Dr. Reddy's Laboratories (RDY) at 1.93 runs in the tighter-liquidity quartile — a thinner cushion against current liabilities for RDY.

Both Dr. Reddy's Laboratories (RDY) at 0.19 and Revolution Medicines (RVMD) at 0.50 fund their balance sheets with roughly industry-typical debt-to-equity mixes.

Financial Strength Metrics

Dividends

Revolution Medicines (RVMD) pays no dividend (yield 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Dr. Reddy's Laboratories (RDY) reports a yield of 55.06%, ranking against industry peers normally.

Revolution Medicines (RVMD) pays no dividend (payout 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Dr. Reddy's Laboratories (RDY) reports a payout of 22.72%, ranking against industry peers normally.

Dividend Metrics

Valuation

An earnings multiple is available for just one side: Dr. Reddy's Laboratories (RDY) trades at 41.42 times trailing earnings, ranked against its peers, while Revolution Medicines (RVMD) has no P/E ratio this period.

Dr. Reddy's Laboratories (RDY) at 0.04 sits in the cheaper P/S ratio quartile while Revolution Medicines (RVMD) at 210.51 prices above its industry range — a wide gap in sales valuation between them.

Measured against book value, both Dr. Reddy's Laboratories (RDY) at 18.16 and Revolution Medicines (RVMD) at 17.31 look expensive — each P/B ratio sits above its industry’s benchmark range.

Valuation Metrics